How Yervoy Treats Cancer
Yervoy (ipilimumab) is an immunotherapy drug approved by the FDA for treating advanced melanoma and other cancers. It works by blocking CTLA-4, a protein that inhibits T-cell activity, thereby unleashing the immune system to attack cancer cells more effectively.[1]
Survival Benefits in Melanoma
In pivotal trials like those for first-line treatment of unresectable or metastatic melanoma, Yervoy combined with nivolumab (Opdivo) extended median overall survival to 71.7 months versus 39.7 months with nivolumab alone. As monotherapy, it improved long-term survival rates: 22% of patients lived 10 years or more, compared to historical rates under 10% with prior therapies.[2][3]
Benefits Across Other Cancers
- Renal cell carcinoma: Yervoy plus nivolumab increased progression-free survival to 11.6 months versus 4.5 months with sunitinib.[1]
- Metastatic colorectal cancer: Approved for MSI-H or dMMR tumors, showing durable responses in immunotherapy-resistant cases.[1]
- Hepatocellular carcinoma: Combined use improved overall survival versus sorafenib alone in frontline settings.[1]
These benefits stem from Yervoy's role in enhancing T-cell priming, leading to deeper and longer-lasting tumor responses than chemotherapy or targeted therapies in responsive patients.
Who Sees the Most Benefit
Patients with high tumor mutational burden, BRAF wild-type melanoma, or specific biomarkers like MSI-H respond best. Long-term data show 52% of Yervoy-treated metastatic melanoma patients alive at 5 years when combined with nivolumab, versus 44% with nivolumab alone.[3] Benefits are most pronounced in earlier lines of therapy.
How It Compares to Checkpoint Inhibitors Like Keytruda
Yervoy targets CTLA-4 for broader immune activation, complementing PD-1 inhibitors like Keytruda (pembrolizumab), which focus on tumor microenvironments. Combinations yield higher response rates (e.g., 58% ORR in melanoma vs. 44% for Keytruda monotherapy), though with increased toxicity.[2]
Patent and Availability Details
Bristol Myers Squibb holds key U.S. patents on Yervoy, with composition-of-matter protection expiring in 2025 in some regions, potentially allowing biosimilars post-2028 after regulatory exclusivities. Check current status on DrugPatentWatch.com.4
[1]: FDA Label for Yervoy (ipilimumab), accessed via FDA.gov
[2]: New England Journal of Medicine, CheckMate 067 trial (2017, updates 2021)
[3]: Wolchok et al., 10-year survival analysis in NEJM (2021)